MAIA Biotechnology, Inc.
MAIA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001878313
In the last 90 days, MAIA Biotechnology, Inc. insiders filed 5 open-market purchases and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $19.4M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding MAIA Biotechnology, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 20 | 19 | −1 |
| Shares | 2.28M | 2.37M | +89.4K (+3.9%) |
| Value | $3.95M | $3.49M | −$465.1K (−11.8%) |
New holders (3)
Institutions that held MAIA Biotechnology, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 11,615 | $17.9K | 0.00% |
| Curio Wealth, LLC | 2,000 | $3.08K | 0.00% |
| Citigroup Inc | 530 | $816 | 0.00% |
Sold out (4)
Institutions that held MAIA Biotechnology, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Jane Street Group, LLC | 28,783 | $51.8K |
| UBS Group AG | 2,120 | $3.82K |
| Raymond James Financial Inc | 100 | $180 |
| JPMorgan Chase & Co | 50 | $90 |